Drug regulators and policymakers have long struggled to find payment models that incentivize the development of novel antimicrobials, given that these medicines are designed to be used sparingly and therefore come with poor financial returns for the companies that develop them.
In England, a “Netflix-style” subscription model is being piloted for two new antimicrobials, Shionogi & Co’s Fetcroja (cefiderocol) and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?